Unique ID issued by UMIN | UMIN000008786 |
---|---|
Receipt number | R000010300 |
Scientific Title | WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan |
Date of disclosure of the study information | 2012/08/28 |
Last modified on | 2022/09/05 10:59:41 |
WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan
WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan
WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan
WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan
Japan |
Advanced colorectal cancer
Gastroenterology | Hematology and clinical oncology |
Malignancy
YES
To investigate the prognostic and predictive biomarkers for colorectal cancer treated with panitumumab plus irinotecan or cetuximab plus irinotecan
Others
Biomarker study
Exploratory
Not applicable
To evaluate the correlation between the efficacy or safety and the genetic polymorphism in patients with cetuximab plus irinotecan or panitumumab plus irinotecan therapy.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Those who participate in the WJOG6510G and give informed consent to the current study are qualified.
Not applicable
120
1st name | |
Middle name | |
Last name | Hiroya Taniguchi |
Aichi Cancer Center Hospital
Department of Clinical Oncology
1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681 Japan
055-989-5222
h.taniguchi@aichi-cc.jp
1st name | |
Middle name | |
Last name | Shinichiro Nakamura |
West Japan Oncology Group
datacenter
Namba Plaza Bldg.3F 1-5-7,Motomachi Naniwa-ku, Osaka
06-6633-7400
datacenter@wjog.jp
West Japan Oncology Group
None
Self funding
NO
2012 | Year | 08 | Month | 28 | Day |
Unpublished
Completed
2012 | Year | 08 | Month | 18 | Day |
2012 | Year | 09 | Month | 24 | Day |
2013 | Year | 05 | Month | 01 | Day |
2017 | Year | 05 | Month | 01 | Day |
To investigate the prognostic and predictive biomarkers for colorectal cancer treated with panitumumab plus irinotecan or cetuximab plus irinotecan
2012 | Year | 08 | Month | 28 | Day |
2022 | Year | 09 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010300
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |